Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12498325 | 0.78 | EGLN2 (0.36) | TDO2IDO1EGLN2ERBB2 | |
| SCHEMBL25167044 | 0.76 | TDO2 (0.35) | TDO2IDO1EGLN2 | |
| SCHEMBL29672973 | 0.75 | KDM4E (0.40) | TDO2IDO1EGLN2ERBB2 | |
| SCHEMBL3095407 | 0.75 | KDM4E (0.40) | TDO2IDO1EGLN2ERBB2 | |
| SCHEMBL14842294 | 0.75 | TDO2 (0.33) | TDO2IDO1EGLN2ERBB2 | |
| SCHEMBL2881406 | 0.75 | CCR1 (0.35) | TDO2IDO1EGLN2ERBB2 | |
| SCHEMBL17868286 | 0.75 | TDO2 (0.39) | TDO2IDO1EGLN2ERBB2 | |
| SCHEMBL6168706 | 0.75 | CYP11B1 (0.33) | TDO2ERBB2 | |
| SCHEMBL27914135 | 0.75 | CYP11B1 (0.33) | TDO2ERBB2 | |
| SCHEMBL29209811 | 0.72 | MBOAT4 (0.34) | TDO2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4638448-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | disclosed |
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-4558492-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| CN-119654315-A | 3- (6-Pyridin-3-yl) -2- [4- (4-methyl-4H-1, 2, 4-triazol-3-yl) piperidin-1-yl ] benzonitrile derivatives and similar compounds as QPCTL and QPCT inhibitors for the treatment of cancer | 858治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4479388-A1 | ANTIVIRAL NAPHTHYRIDINONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-114555570-B | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-1898198-A | Alpha-hydroxy amides as bradykinin antagonists or inverse agonists | MERCK & CO INC (US) | 2007-01-17 | — | — | CN | disclosed |
| US-7163951-B2 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | MERCK & CO., INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1720856-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1706372-A1 | ALPHA-HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS | Merck & Co., Inc. (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20050288305-A1 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | MERCK SHARP & DOHME CORP. | 2005-12-29 | — | — | US | disclosed |
| CN-1678320-A | N-biarylmethylaminocycloalkaneamide derivatives | MERCK & CO INC (US) | 2005-10-05 | — | — | CN | disclosed |
| WO-2005077050-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005063690-A1 | ALPHA-HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS | MERCK & CO., INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1545538-A2 | N-BIARYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004019868-A2 | N-BIARYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | TDO2 2361/4885IDO1 581/4885EGLN2 4187/4885 |
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | TDO2 4785/4885IDO1 3933/4885EGLN2 1351/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | TDO2 3915/4885IDO1 3985/4885EGLN2 1304/4885 |
| US-20050288305-A1 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, LTB4R2 | TDO2 2846/4885IDO1 809/4885EGLN2 785/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | TDO2 4769/4885IDO1 3863/4885EGLN2 1203/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | TDO2 4387/4885IDO1 3162/4885EGLN2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.